Zimmer Q3 sales up, but costs continue to hurt profit
This article was originally published in Clinica
Executive Summary
Orthopedic firm Zimmer’s third quarter was “solid as expected,” noted Morgan Stanley analyst David Lewis, with sales of $1.07bn up 5% year-on-year and beating analyst expectations of $1.06bn.